Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Purchased by Barclays PLC

Barclays PLC increased its position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 367.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 124,141 shares of the company’s stock after buying an additional 97,565 shares during the period. Barclays PLC owned about 0.23% of Fulcrum Therapeutics worth $443,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. increased its holdings in Fulcrum Therapeutics by 223.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 569,185 shares of the company’s stock valued at $2,032,000 after buying an additional 393,202 shares during the last quarter. State Street Corp boosted its holdings in Fulcrum Therapeutics by 61.4% in the third quarter. State Street Corp now owns 1,680,229 shares of the company’s stock valued at $5,998,000 after purchasing an additional 638,955 shares in the last quarter. Braidwell LP purchased a new position in Fulcrum Therapeutics in the third quarter valued at approximately $3,817,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Fulcrum Therapeutics during the 3rd quarter worth approximately $474,000. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Fulcrum Therapeutics during the 3rd quarter worth $721,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. HC Wainwright reaffirmed a “neutral” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $9.33.

Fulcrum Therapeutics Stock Performance

Shares of Fulcrum Therapeutics stock opened at $3.96 on Friday. Fulcrum Therapeutics, Inc. has a one year low of $2.86 and a one year high of $13.70. The company has a market cap of $213.60 million, a P/E ratio of -12.77 and a beta of 2.06. The firm has a fifty day moving average of $4.06 and a two-hundred day moving average of $5.46.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.